| 1 |
Ekberg H, Kyllönen L, Madsen S, et al. Increased prevalence of gastrointestinal symptoms associated with impaired quality of life in renal transplant recipients[J]. Transplantation, 2007，83(3):282-289.
|
| 2 |
Zhu Y, Zhou Y, Zhang L, et al. Efficacy of interventions for adherence to the immunosuppressive therapy in kidney transplant recipients: a meta-analysis and systematic review[J]. J Investig Med, 2017，65(7):1049-1056.
|
| 3 |
Nevins TE, Nickerson PW, Dew MA. Understanding medication nonadherence after kidney transplant[J]. J Am Soc Nephrol, 2017，28(8):2290-2301.
|
| 4 |
Kim JE, Ha J, Kim YS, et al. Effect of severe diarrhea on kidney transplant outcomes[J]. Nephrology, 2019.[Epub ahead of print]
|
| 5 |
Malinowski M, Martus P, Lock JF, et al. Systemic influence of immunosuppressive drugs on small and large bowel transport and barrier function[J]. Transpl Int, 2011, 24(2):184-193.
|
| 6 |
Angarone M, Snydman DR; AST ID Community of Practice. Diagnosis and management of diarrhea in solid-organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019，33(9):e13550.
|
| 7 |
Tielemans MM, van Boekel GAJ, van Gelder T, et al. Immunosuppressive drugs and the gastrointestinal tract in renal transplant patients[J]. Transplant Rev (Orlando), 2019, 33(2):55-63.
|
| 8 |
Ginsburg PM, Thuluvath PJ. Diarrhea in liver transplant recipients: etiology and management[J]. Liver Transpl, 2005，11(8):881-890.
|
| 9 |
Maes BD, Vanwalleghem J, Kuypers D, et al. Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine[J]. Transplantation, 1999，68(10):1482-1485.
|
| 10 |
Park JM, Lake KD, Cibrik DM. Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes[J]. Ther Drug Monit, 2008，30(5):591-596.
|
| 11 |
Camilleri M, Parkman HP, Shafi MA, et al; American College of Gastroenterology. Clinical guideline: management of gastroparesis[J]. Am J Gastroenterol, 2013, 108(1):18-37.
|
| 12 |
Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2[J]. Am J Transplant, 2005，5(5):987-994.
|
| 13 |
Kumar M, Chapman A, Javed S, et al. The investigation and treatment of diabetic gastroparesis[J]. Clin Ther, 2018，40(6):850-861.
|
| 14 |
van Boekel GA, Aarnoutse RE, van der Heijden JJ, et al. Effect of mild diarrhea on tacrolimus exposure[J]. Transplantation, 2012，94(7):763-767.
|
| 15 |
Canaparo R, Finnström N, Serpe L, et al. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum[J]. Clin Exp Pharmacol Physiol, 2007，34(11):1138-1144.
|
| 16 |
Stefanović NZ, Cvetković TP, Jevtović-Stoimenov TM, et al. Investigation of CYP 3A5 and ABCB1 gene polymorphisms in the long-term following renal transplantation: Effects on tacrolimus exposure and kidney function[J]. Exp Ther Med, 2015，10(3):1149-1156.
|
| 17 |
Muller J, Keiser M, Drozdzik M, et al. Expression, regulation and function of intestinal drug transporters: an update[J]. Biol Chem, 2017，398(2):175-192.
|
| 18 |
Mouly S, Paine MF. P-glycoprotein increases from proximal to distal regions of human small intestine[J]. Pharm Res, 2003，20(10):1595-1599.
|
| 19 |
Kawauchi S, Nakamura T, Miki I, et al. Downregulation of CYP3A and P-glycoprotein in the secondary inflammatory response of mice with dextran sulfate sodium-induced colitis and its contribution to cyclosporine A blood concentrations[J]. J Pharmacol Sci, 2014，124(2):180-191.
|
| 20 |
Evers R, Piquette-Miller M, Polli JW, et al. Disease-associated changes in drug transporters may impact the pharmacokinetics and/or toxicity of drugs: a White Paper from the International Transporter Consortium[J]. Clin Pharmacol Ther, 2018，104(5):900-915.
|
| 21 |
Guo Y, Crnkovic CM, Won KJ, et al. Commensal gut bacteria convert the immunosuppressant tacrolimus to less potent metabolites[J]. Drug Metab Dispos, 2019，47(3):194-202.
|
| 22 |
Lee JR, Muthukumar T, Dadhania D, et al. Gut microbiota and tacrolimus dosing in kidney transplantation[J]. PLoS One, 2015, 10(3):e0122399.
|
| 23 |
Lee JR, Muthukumar T, Dadhania D, et al. Gut microbial community structure and complications after kidney transplantation: a pilot study[J]. Transplantation, 2014，98(7):697-705.
|
| 24 |
Lee JR, Magruder M, Zhang L, et al. Gut microbiota dysbiosis and diarrhea in kidney transplant recipients[J]. Am J Transplant, 2019，19(2):488-500.
|
| 25 |
Rangel EB, Melaragno CS, Sá JR, et al. Mycophenolate mofetil versus enteric-coated mycophenolate sodium after simultaneous pancreas-kidney transplantation[J]. Transplant Proc, 2009，41(10):4265-4269.
|
| 26 |
Chan L, Mulgaonkar S, Walker R, et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium[J]. Transplantation, 2006, 81(9):1290-1297.
|
| 27 |
孟凡航，郭雪坤，陈志勇，等. 麦考酚钠肠溶片治疗肾移植后远期吗替麦考酚酯相关性腹泻患者的临床疗效[J]. 世界华人消化杂志，2014，22(30):4691-4694.
|
| 28 |
Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action[J]. Immunopharmacology, 2000，47(2-3):85-118.
|
| 29 |
Aiyangar A, Rajput P, Shah BV. Mycophenolate induced diarrhoea[J]. J Assoc Physicians India, 2010，58:192-194.
|
| 30 |
Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management[J]. Drug Saf, 2001，24(9):645-663.
|
| 31 |
Heischmann S, Dzieciatkowska M, Hansen K, et al. The immunosuppressant mycophenolic acid alters nucleotide and lipid metabolism in an intestinal cell model[J]. Sci Rep, 2017，7:45088.
|
| 32 |
Satoh S, Tada H, Murakami M, et al. The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation[J]. Transplant Proc, 2005，37(4):1751-1753.
|
| 33 |
Cristelli MP, Tedesco-Silva H, Medina-Pestana JO, et al. Safety profile comparing azathioprine and mycophenolate in kidney transplant recipients receiving tacrolimus and corticosteroids[J]. Transpl Infect Dis, 2013，15(4):369-378.
|
| 34 |
芦泽兰，乔宇琪，冉志华. Th17细胞和肠道菌群在炎症性肠病发病中的作用[J]. 胃肠病学，2015, 20(10):619-621.
|
| 35 |
蒋学佩，吴小丽，黄智铭. Treg细胞和Th17细胞在炎症性肠病治疗中的作用[J]. 胃肠病学，2018, 23(2):109-112.
|
| 36 |
Abadja F, Atemkeng S, Alamartine E, et al. Impact of mycophenolic acid and tacrolimus on Th17-related immune response[J]. Transplantation, 2011，92(4):396-403.
|